Harvard Bioscience (HBIO) Income from Continuing Operations (2010 - 2026)
Harvard Bioscience (HBIO) posted quarterly Income from Continuing Operations of 3424000.0 for Q1 2026, up 93.19% year-over-year from 1772329.83 in Q1 2025, and down 21.5% quarter-over-quarter from 2818000.0 in Q4 2025.
Harvard Bioscience (HBIO) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has reported Income from Continuing Operations for 17 consecutive years, with 3424000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 93.19% year-over-year to 3424000.0; the TTM figure through Mar 2026 stood at 9757000.0 (up 83.08% YoY), while the FY2025 annual figure was 56700000.0, down 368.79% from the prior year.
- Income from Continuing Operations slipped to 3424000.0 in Q1 2026 per HBIO's latest filing, from 2818000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 2421000.0 in Q2 2022 and bottomed at 50294000.0 in Q1 2025.
- Historically, Income from Continuing Operations has averaged 4927470.59 across 5 years, with a median of 2284000.0 in 2025.
- On a YoY basis, Income from Continuing Operations climbed as much as 660.42% in 2022 and fell as far as 1902.94% in 2022.
- Harvard Bioscience's Income from Continuing Operations stood at 1666000.0 in 2022, then soared by 72.03% to 466000.0 in 2023, then surged by 177.25% to 360000.0 in 2024, then tumbled by 882.78% to 2818000.0 in 2025, then retreated by 21.5% to 3424000.0 in 2026.
- Business Quant data shows HBIO's Income from Continuing Operations at 3424000.0 in Q1 2026, 2818000.0 in Q4 2025, and 1231000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 823.20 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 452.00 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | - |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 383.43 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 139.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 147.90 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 93.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | -77.90 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 135.00 Mn |
| 10 | Harvard Bioscience | 33.45 Mn | 26.94 Mn | 12.63 Mn | -2.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.91 Mn |
| Mar 31, 2026 | -3.42 Mn |
| Dec 31, 2025 | -2.82 Mn |
| Sep 30, 2025 | -1.23 Mn |
| Jun 30, 2025 | -2.28 Mn |
| Mar 31, 2025 | -50.29 Mn |
| Dec 31, 2024 | 360,000.00 |
| Sep 30, 2024 | -4.79 Mn |
| Jun 30, 2024 | -2.93 Mn |
| Mar 31, 2024 | -4.69 Mn |
| Dec 31, 2023 | -466,000.00 |
| Sep 30, 2023 | -1.24 Mn |
| Jun 30, 2023 | -998,000.00 |
| Mar 31, 2023 | 607,000.00 |
| Dec 31, 2022 | -1.67 Mn |
| Sep 30, 2022 | -3.41 Mn |
| Jun 30, 2022 | 2.42 Mn |
| Mar 31, 2022 | -6.92 Mn |
| Dec 31, 2021 | 1.14 Mn |
| Sep 30, 2021 | -170,000.00 |